Serum P-selectin Level During Controlled Ovarian Hyperstimulation – a Preliminary Report
Article first published online: 26 JUL 2004
American Journal of Reproductive Immunology
Volume 52, Issue 2, pages 139–142, August 2004
How to Cite
Orvieto, R., Badir, W., Bar, J., La Marca, A., Ashkenazi, J., Avrech, O. M. and Fisch, B. (2004), Serum P-selectin Level During Controlled Ovarian Hyperstimulation – a Preliminary Report. American Journal of Reproductive Immunology, 52: 139–142. doi: 10.1111/j.1600-0897.2004.00194.x
- Issue published online: 26 JUL 2004
- Article first published online: 26 JUL 2004
- Submitted March 4, 2004; revised April 29, 2004; accepted May 3, 2004.
- ovulation induction;
Objective: To measure levels of serum P-selectin in patients undergoing controlled ovarian hyperstimulation (COH) cycles and to determine their possible correlation to COH variables.
Setting: Large university-based infertility and in vitro fertilization unit.
Patients: Fourteen consecutive patients undergoing our routine COH protocol for unexplained infertility.
Interventions and Main Outcome Measures: Blood was drawn three times during the COH cycle: (1) day 2 or 3 of the menstrual cycle, before gonadotropin treatment (Day-0); (2) day of or prior to human chorionic gonadotropin (hCG) administration (Day-hCG); and (3) day of ovulation (Day-OVU). Serum levels of sex steroids and P-selectin were compared among the three time points. P-selectin was measured with a commercial quantitative sandwich immunoassay technique. To reduce interpatient variability, the percent difference between the Day-0 (non-stimulated, basal) level and the Day-hCG and Day-OVU levels was calculated.
Results: P-selectin level on Day-hCG was significantly higher than on Day-0 (P < 0.05) and non-significantly higher than on Day-OVU (P < 0.12). No significant correlations were observed between serum P-selectin and patient age, amount of gonadotropins used, or estradiol or progesterone level.
Conclusion: The increase in serum P-selectin level during COH until peak estradiol suggests that COH may potentiate a state of platelet activation which is substantially attenuated after hCG administration.